A new blood test for Alzheimer’s: Measuring mitochondrial health
A correction notice has been published for a study proposing a novel blood-based biomarker for Alzheimer’s disease. The original research described a “mitochondrial functional index” derived from blood samples, aiming to provide a measurable indicator of the cellular energy dysfunction commonly observed in Alzheimer’s pathology. This approach seeks to move beyond traditional protein markers like amyloid and tau by assessing a core component of neuronal health and vulnerability.
Why it might matter to you:
The pursuit of a mitochondrial function biomarker represents a strategic shift towards capturing a dynamic disease process rather than a static pathological deposit. For professionals focused on clinically actionable diagnostics, this concept underscores the potential value of functional assays that could correlate with disease progression and treatment response. It highlights an ongoing research direction where blood-based readouts of cellular physiology are being explored to complement structural imaging and clinical data.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
